Skip to content
OpenCapital
Get started

Ironwood Pharmaceuticals IRWD Cash Provided by (Used in) Financing Activity, Including Discontinued Operation

Cash Provided by (Used in) Financing Activity, Including Discontinued Operation at other companies

Bausch Health Companies logo
Bausch Health CompaniesBHC
-$100M+31.5%
Lexicon Pharmaceuticals logo
Lexicon PharmaceuticalsLXRX
$88.76M+15,617%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$57.26M+2,504%
Gilead Sciences logo
Gilead SciencesGILD
——

Other financials

Income statement

See full
Revenue$106.5M+159%
Operating income$72.6M+349%
Net income$40.8M+209%
EPS (diluted)$0.24+204%

Balance sheet

See full
Cash & equivalents$220.5M+103%
Total debt$212.4M+1,323%
Total equity-$217.1M+35.0%
Total assets$434.6M+32.8%

Cash flow

See full
Operating cash flow$5.1M-74.3%
CapEx-—
Free cash flow$74.6M+390%

Valuation

See full
Market cap$632.12M+457%
Enterprise value$624M+3,024%
P/E6.2×—
P/S1.8×+1.4×

Profitability

See full
Gross margin99.2%—
Operating margin55.4%+38.7pp
Net margin28.3%+22.3pp
FCF margin24.7%-11.1pp

Returns & leverage

See full
Return on equity29.7%-138pp
Debt / equity0×-0.5×
Current ratio1.4×-1.9×

Where this comes from

Reported directly by Ironwood Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Ironwood Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ironwood Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ironwood Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation?
Ironwood Pharmaceuticals (IRWD) reported cash provided by (used in) financing activity, including discontinued operation of $122K in Q4 2025.
How has Ironwood Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation changed year-over-year?
Ironwood Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation increased by 100.8% year-over-year, from -$14.89M to $122K.
What is the long-term trend for Ironwood Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation?
Over 3 years (2021 to 2025), Ironwood Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation has grown at a -63.8% compound annual growth rate (CAGR), from -$4.55M to $216K.
What does cash provided by (used in) financing activity, including discontinued operation mean?
This metric measures the net cash flow between the company and its capital providers, including proceeds from debt or equity issuance and payments for dividends or share repurchases. It highlights how the company finances its operations and returns value to shareholders.